Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas | Zendy

Gregory K. Friedman | Zendy; James M. Johnston | Zendy; Asim K. Bag | Zendy; Joshua D. Bernstock | Zendy; Rong Li | Zendy; Inmaculada Aban | Zendy; Kara Kachurak | Zendy; Li Nan | Zendy; KyungDon Kang | Zendy; Stacie K. Totsch | Zendy; Charles Schlappi | Zendy; Allison Martin | Zendy; Devang Pastakia | Zendy; René McNall-Knapp | Zendy; Sameer Farouk Sait | Zendy; Yasmin Khakoo | Zendy; Matthias A. Karajannis | Zendy; Karina Woodling | Zendy; Joshua D. Palmer | Zendy; Diana S. Osorio | Zendy; Jeffrey R. Leonard | Zendy; Mohamed S Abdelbaki | Zendy; Avi MadanSwain | Zendy; T. Prescott Atkinson | Zendy; Richard J. Whitley | Zendy; John B. Fiveash | Zendy; James M. Markert | Zendy; G. Yancey Gillespie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

Author(s) -

Gregory K. Friedman,

James M. Johnston,

Asim K. Bag,

Joshua D. Bernstock,

Rong Li,

Inmaculada Aban,

Kara Kachurak,

Li Nan,

KyungDon Kang,

Stacie K. Totsch,

Charles Schlappi,

Allison Martin,

Devang Pastakia,

René McNall-Knapp,

Sameer Farouk Sait,

Yasmin Khakoo,

Matthias A. Karajannis,

Karina Woodling,

Joshua D. Palmer,

Diana S. Osorio,

Jeffrey R. Leonard,

Mohamed S Abdelbaki,

Avi MadanSwain,

T. Prescott Atkinson,

Richard J. Whitley,

John B. Fiveash,

James M. Markert,

G. Yancey Gillespie

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2024947

Subject(s) - oncolytic virus , hsl and hsv , medicine , oncology , cancer research , virology , virus , tumor cells

Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research